# INmune Bio (INMB) — Earnings

INMB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/inmb/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.05 |
| EPS estimate | −$0.21 |
| EPS surprise | +75.81% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1711754/000121390026086135/ea0298894-10q_inmune.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d46eaffd-9ae3-8f55-e85d-dc6fc7ba86f7.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.21 | −$0.05 | 75.81% | — | — |
| Q1 2026 | May 7, 2026 | −$0.25 | −$0.20 | 18.37% | — | — |
| Q4 2025 | Mar 30, 2026 | −$0.27 | −$0.20 | 26.74% | — | — |
| Q3 2025 | Oct 30, 2025 | −$0.32 | −$0.24 | 24.53% | — | — |
| Q2 2025 | Aug 7, 2025 | −$0.38 | −$1.05 | -173.44% | — | — |
| Q1 2025 | May 8, 2025 | −$0.47 | −$0.43 | 8.69% | — | $50,000.00 |
| Q4 2024 | Mar 27, 2025 | −$0.55 | −$0.40 | 26.99% | — | — |
| Q3 2024 | Oct 31, 2024 | −$0.51 | −$0.60 | -18.41% | $333.00 | — |
| Q2 2024 | Aug 1, 2024 | −$0.63 | −$0.50 | 20.63% | $14,000.00 | — |
| Q1 2024 | May 9, 2024 | −$0.54 | −$0.61 | -14.02% | $28,000.00 | $14,000.00 |
| Q4 2023 | Mar 28, 2024 | −$0.43 | −$0.47 | -10.15% | $43,000.00 | $25,000.00 |
| Q3 2023 | Nov 1, 2023 | −$0.39 | −$0.48 | -22.04% | $46,000.00 | $43,000.00 |
| Q2 2023 | Aug 7, 2023 | −$0.40 | −$0.36 | 9.21% | $38,000.00 | $46,000.00 |
| Q1 2023 | May 3, 2023 | −$0.02 | −$0.36 | -1700.00% | — | $38,000.00 |
| Q4 2022 | Mar 2, 2023 | −$0.49 | −$0.32 | 34.02% | — | $94,000.00 |
| Q3 2022 | Nov 2, 2022 | −$0.53 | −$0.43 | 18.10% | — | $98,000.00 |
| Q2 2022 | Aug 3, 2022 | −$0.49 | −$0.38 | 21.86% | — | $16,000.00 |
| Q1 2022 | May 5, 2022 | −$0.57 | −$0.39 | 31.11% | — | $163,000.00 |
| Q4 2021 | Mar 3, 2022 | −$0.58 | −$0.57 | 0.96% | — | $183,500.00 |
| Q3 2021 | Nov 3, 2021 | −$0.36 | −$0.55 | -51.64% | $1.4M | $14,000.00 |

## Frequently Asked Questions

### When did INmune Bio (INMB) last report earnings?

INmune Bio last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did INMB beat earnings estimates?

Yes. INmune Bio reported EPS of −$0.05 for Q2 2026 against a −$0.21 estimate — a 75.81% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).